Compare ADMA Biologics Inc (ADMA) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45. The key difference: Vanguard Global ex-US Real Estate Index Fd ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | VNQI | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | — |
52-Week High | $20.38 | $50.76 |
52-Week Low | $7.60 | $43.26 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.50, up 0.38% with mixed technical signals showing a bullish overall trend but bearish moving averages. The ETF offers international real estate diversification with a low 0.12% expense ratio and attractive 4.6% dividend yield. Recent news highlights its cost advantage over competitors and institutional buying interest from Eagle Bay Advisors, which increased its stake by 95.7% in Q4 2025.
VNQI presents a compelling opportunity for yield-seeking investors seeking global real estate exposure at low cost, with recovery potential as global transaction volumes are expected to rise over 10% in 2026. Key risks include currency fluctuations, international economic volatility, and interest rate sensitivity. The ETF's valuation appears reasonable at 11.9x P/E and 0.9x P/B according to Seeking Alpha analysis from May 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
